SciSparc Completes Production Of Its Dronabinol-Based Drug Candidate For Its Clinical Trial On Tourette Syndrome

SciSparc Ltd. SPRC has successfully manufactured clinical batches of its drug candidate SCI-110 to be used in its upcoming multinational, multicenter, phase IIb trial for Tourette syndrome.

SCI-110 batches were manufactured by Procaps Group S.A., under Good Manufacturing Process conditions to comply with the U.S. Food and Drug Administration, the European Medicines Agency and Israeli Ministry of Health rigorous requirements.

The company has already received ethics committee approvals from the Hannover Medical School in Hannover, Germany, and the Tel Aviv Sourasky Medical Center, in Tel Aviv, Israel. The company is currently preparing to submit a request for approval to the Institutional Review Board of Yale University, Connecticut, USA.

Tourette syndrome is a movement and neurobehavioral disorder characterized by chronic motor and vocal tics. With the onset before age 18, about half to two-thirds of Tourette syndrome cases improve during adolescence, while adults are generally more severe patients. Tics may be associated with a premonitory sensation to perform a specific action, which may lead to “relief” once performed.

The objective of this phase IIb randomized, multi-national, multi-center, double-blind, placebo controlled cross-over study is to evaluate the efficacy, safety and tolerability of SciSparc's proprietary drug candidate SCI-110 in adult patients (between 18 and 65 years of age) using oral treatment daily. The patients will be randomized in a 1:1 ratio to receive either SCI-110 or a SCI-110 matched placebo.

The primary efficacy objective of the study will be to assess tic severity change using the Yale global tic severity scale, the most commonly used measure in clinical trials, as a continuous endpoint at week 12 and week 26 of the double-blind phase compared to baseline. The primary safety objective of the study will be to assess absolute and relative frequencies of serious adverse events for the entire population and separately for the SCI-110 and placebo groups. The launch of the trial is subject to approvals by FDA, the German Federal Institute for Drugs and Medical Devices , the Israeli Ministry of Health and Yale’s IRB.

Benzinga's Cannabis Capital Conference Is Back

The most successful cannabis business event in the world, the Benzinga Cannabis Capital Conference, returns to Miami for its 16th edition. This is the place where DEALS GET DONE, where money is raised, M&A starts, and companies meet investors and key partners. Join us at the Fontainebleau Miami Beach Hotel in Florida on April 11-12. Don’t miss out. Secure your tickets now. Prices will surge very soon.

Photo by Esteban López on Unsplash